Exscientia Plc (EXAI)

$5.18

+0.04

(+0.78%)

Market is closed - opens 7 PM, 23 Jul 2024

Performance

  • $4.90
    $5.20
    $5.18
    downward going graph

    5.41%

    Downside

    Day's Volatility :5.68%

    Upside

    0.29%

    downward going graph
  • $3.86
    $9.12
    $5.18
    downward going graph

    25.48%

    Downside

    52 Weeks Volatility :57.68%

    Upside

    43.2%

    downward going graph

Returns

PeriodExscientia Plc
3 Months
18.26%
6 Months
-15.22%
1 Year
-32.2%
3 Years
-80.89%

Highlights

Market Capitalization
649.6M
Book Value
$2.62
Earnings Per Share (EPS)
-1.35
Wall Street Target Price
8.33
Profit Margin
0.0%
Operating Margin TTM
-526.8%
Return On Assets TTM
-18.33%
Return On Equity TTM
-33.23%
Revenue TTM
19.6M
Revenue Per Share TTM
0.16
Quarterly Revenue Growth YOY
-8.200000000000001%
Gross Profit TTM
10.2M
EBITDA
-144.6M
Diluted Eps TTM
-1.35
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.71
EPS Estimate Next Year
-0.71
EPS Estimate Current Quarter
-0.28
EPS Estimate Next Quarter
-0.29

Analyst Recommendation

Buy
    66%Buy
    33%Hold
    0
    0%Sell
Based on 9 Wall street analysts offering stock ratings for Exscientia Plc(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
3
3
3
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 60.81%

Current $5.18
Target $8.33

Company Financials

FY19Y/Y Change
Revenue
15.7M
-
Net Income
-10.9M
-
Net Profit Margin
-69.36%
-
FY20Y/Y Change
Revenue
18.0M
↑ 10.39%
Net Income
-41.4M
↑ 266.64%
Net Profit Margin
-230.39%
↓ 161.03%
FY21Y/Y Change
Revenue
37.0M
↑ 107.98%
Net Income
-66.5M
↑ 62.25%
Net Profit Margin
-179.73%
↑ 50.66%
FY22Y/Y Change
Revenue
32.9M
↑ 20.01%
Net Income
-143.2M
↑ 190.63%
Net Profit Margin
-435.26%
↓ 255.53%
FY23Y/Y Change
Revenue
31.8M
↓ 24.14%
Net Income
-231.0M
↑ 26.7%
Net Profit Margin
-726.94%
↓ 291.68%
Q4 FY22Q/Q Change
Revenue
8.2M
↑ 16.59%
Net Income
-47.1M
↑ 18.89%
Net Profit Margin
-574.39%
↓ 11.1%
Q1 FY23Q/Q Change
Revenue
7.1M
↓ 29.74%
Net Income
-46.6M
↓ 20.08%
Net Profit Margin
-653.41%
↓ 79.02%
Q2 FY23Q/Q Change
Revenue
3.8M
↓ 47.82%
Net Income
-45.4M
↓ 4.44%
Net Profit Margin
-1.2K%
↓ 543.23%
Q3 FY23Q/Q Change
Revenue
8.9M
↑ 195.48%
Net Income
-31.2M
↓ 13.22%
Net Profit Margin
-351.43%
↑ 845.21%
Q4 FY23Q/Q Change
Revenue
3.1M
↓ 72.64%
Net Income
-52.4M
↑ 31.78%
Net Profit Margin
-1.7K%
↓ 1341.37%
Q1 FY24Q/Q Change
Revenue
5.3M
↑ 117.7%
Net Income
-21.0M
↓ 48.93%
Net Profit Margin
-397.11%
↑ 1295.69%
FY19Y/Y Change
Total Assets
71.3M
-
Total Liabilities
33.4M
-
FY20Y/Y Change
Total Assets
144.4M
↑ 94.81%
Total Liabilities
35.7M
↑ 2.79%
FY21Y/Y Change
Total Assets
865.1M
↑ 505.0%
Total Liabilities
99.7M
↑ 182.3%
FY22Y/Y Change
Total Assets
784.6M
↑ 22.43%
Total Liabilities
206.3M
↑ 179.27%
FY23Y/Y Change
Total Assets
829.0M
↓ 17.02%
Total Liabilities
251.6M
↓ 4.22%
Q4 FY22Q/Q Change
Total Assets
784.6M
↑ 4.45%
Total Liabilities
206.3M
↑ 14.27%
Q1 FY23Q/Q Change
Total Assets
747.3M
↓ 23.11%
Total Liabilities
192.7M
↓ 24.59%
Q2 FY23Q/Q Change
Total Assets
711.4M
↓ 6.52%
Total Liabilities
185.0M
↓ 5.72%
Q3 FY23Q/Q Change
Total Assets
550.1M
↓ 2.45%
Total Liabilities
157.2M
↑ 7.16%
Q4 FY23Q/Q Change
Total Assets
650.3M
↓ 7.16%
Total Liabilities
197.3M
↓ 1.38%
Q1 FY24Q/Q Change
Total Assets
598.1M
↓ 7.28%
Total Liabilities
180.6M
↓ 7.76%
FY19Y/Y Change
Operating Cash Flow
12.1M
-
Investing Cash Flow
-2.2M
-
Financing Cash Flow
-251.0K
-
FY20Y/Y Change
Operating Cash Flow
-39.8M
↓ 417.12%
Investing Cash Flow
-5.1M
↑ 120.42%
Financing Cash Flow
104.6M
↓ 40188.77%
FY21Y/Y Change
Operating Cash Flow
-9.0M
↓ 77.17%
Investing Cash Flow
-35.9M
↑ 609.37%
Financing Cash Flow
719.6M
↑ 594.67%
Q4 FY22Q/Q Change
Operating Cash Flow
-58.2M
↓ 25.55%
Investing Cash Flow
95.7M
↓ 1393.21%
Financing Cash Flow
-1.0M
↑ 591.55%
Q1 FY23Q/Q Change
Operating Cash Flow
-53.7M
↓ 25.43%
Investing Cash Flow
118.6M
↑ 0.0%
Financing Cash Flow
-904.2K
↓ 27.27%
Q2 FY23Q/Q Change
Operating Cash Flow
-52.1M
↓ 4.86%
Investing Cash Flow
120.8M
↑ 0.0%
Financing Cash Flow
-1.1M
↑ 19.59%
Q3 FY23Q/Q Change
Operating Cash Flow
-34.2M
↓ 17.25%
Investing Cash Flow
-105.5M
↓ 210.14%
Financing Cash Flow
-919.0K
↑ 5.27%

Technicals Summary

Sell

Neutral

Buy

Exscientia Plc is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Exscientia Plc
Exscientia Plc
-1.15%
-15.22%
-32.2%
-80.89%
-80.89%
Moderna, Inc.
Moderna, Inc.
-10.58%
20.19%
-0.41%
-64.88%
800.74%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
0.55%
12.06%
47.12%
82.44%
245.9%
Novo Nordisk A/s
Novo Nordisk A/s
-6.4%
26.39%
64.35%
193.51%
440.83%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
4.41%
12.78%
38.89%
147.34%
182.99%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Exscientia Plc
Exscientia Plc
NA
NA
NA
-0.71
-0.33
-0.18
NA
2.62
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.45
31.45
1.46
44.4
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
45.05
45.05
2.36
3.45
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.94
31.94
0.53
17.05
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Exscientia Plc
Exscientia Plc
Buy
$649.6M
-80.89%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$46.4B
800.74%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$117.2B
245.9%
31.45
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$591.7B
440.83%
45.05
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.9B
182.99%
31.94
39.46%

Institutional Holdings

  • SoftBank Group Corp

    4.50%
  • LAURION CAPITAL MANAGEMENT LP

    4.28%
  • Baillie Gifford & Co Limited.

    3.62%
  • Junked Platinum Investment Management Ltd

    3.12%
  • Woodline Partners LP

    1.31%
  • Bill & Melinda Gates Foundation

    1.26%

Company Information

at the forefront of small molecule drug discovery we are the first company to automate drug design, surpassing conventional human endeavour. our ai driven systems actively learn best practice from vast repositories of discovery data and are further enhanced with knowledge acquired from seasoned drug hunters. with better information to hand than any researcher could acquire individually, our knowledge-driven systems design millions of novel, project-specific compounds and pre-assess each for predicted potency, selectivity, adme and other key criteria. from this, a selection of the best, information-rich compounds are selected for synthesis and assay. with new experimental data generated, the results are integrated and the next design cycle initiated. rapid design-make-test cycles ensure unparalleled progress towards desired project goals. exscientia has already delivered exceptional productivity, generating candidates in roughly one-quarter of the time of traditional approaches.

Organization
Exscientia Plc
Employees
483
CEO
Dr. David Hallett Ph.D.
Industry
Healthcare

FAQs